827 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B Downtrend
Article Searches
Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer http://www.zacks.com/stock/news/353843/mercks-keytruda-gets-fda-priority-review-for-head-neck-cancer?cid=CS-ZC-FT-353843 Feb 12, 2019 - Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Stock Market News For Feb 12, 2019 http://www.zacks.com/stock/news/353887/stock-market-news-for-feb-12-2019?cid=CS-ZC--353887 Feb 12, 2019 - Markets closed mostly higher on Monday as fresh rounds of trade talks between the United States and China began.
Incyte Down as FDA Extends Review Period of Jakafi for GVHD http://www.zacks.com/stock/news/353405/incyte-down-as-fda-extends-review-period-of-jakafi-for-gvhd?cid=CS-ZC-FT-353405 Feb 08, 2019 - The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.
Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark http://www.zacks.com/stock/news/353400/seattle-genetics-sgen-q4-loss-widens-revenues-top-mark?cid=CS-ZC-FT-353400 Feb 08, 2019 - Seattle Genetics (SGEN) incurs wider-than-expected loss in Q4 but rides high on revenue beat.
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs http://www.zacks.com/stock/news/353203/pharma-stock-roundup-q4-earnings-at-mrk-lly-chmp-nod-for-several-drugs?cid=CS-ZC-FT-353203 Feb 08, 2019 - Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $18. ... http://www.gurufocus.com/news/811679/merck--co-inc-mrk-chairman-president--ceo-kenneth-c-frazier-sold-181-million-of-shares Feb 06, 2019 - Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $18.1 million of Shares, Stocks: MRK, release date:Feb 06, 2019
Flip the Script: Drugmakers Blame Middlemen for Price Increases https://www.wsj.com/articles/flip-the-script-drugmakers-blame-middlemen-for-price-hikes-11549364401?mod=pls_whats_news_us_business_f Feb 05, 2019 - Under pressure over rising drug prices, pharmaceutical companies are pushing a new defense: They’re not raising prices to make money or to cover research costs, but rather to pay a cut to middlemen in the supply chain.
Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer http://www.zacks.com/stock/news/352085/mercks-keytruda-clinches-chmp-nod-for-difficult-lung-cancer?cid=CS-ZC-FT-352085 Feb 05, 2019 - Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.
Why Merck (MRK) is a Great Dividend Stock Right Now http://www.zacks.com/stock/news/351811/why-merck-mrk-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-351811 Feb 04, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Stock Market News For Feb 4, 2019 http://www.zacks.com/stock/news/351843/stock-market-news-for-feb-4-2019?cid=CS-ZC--351843 Feb 04, 2019 - Markets closed mostly in the green on Friday after the release of stellar economic data boosted investor sentiment.

Pages: 1...4567891011121314...83

<<<Page 9>